Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial

European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies
J-H LeeS U Kwon

Abstract

Biological aspirin resistance (AR) has been recognized as an important cause of clinical AR. Recent studies have reported the beneficial effects of cilostazol for the prevention of cardiovascular diseases. This study investigated whether addition of cilostazol to aspirin in ischaemic stroke patients can reduce AR. In this double-blind multicenter trial, 244 aspirin users with ischaemic stroke were randomly assigned to receive cilostazol 100 mg twice daily or to placebo. Antiplatelet function was assessed using the VerifyNow Aspirin system. The primary end-point was the incidence of AR, which was measured as aspirin resistance unit (ARU) > or =550 after 4-week treatment. The incidence of AR after treatment in cilostazol group was not significantly different from that in placebo (8.8% vs. 10.9%, P = 0.578). However, AR decreased from 12.8% to 8.8% in cilostazol group, whereas it was not changed in the placebo group. The mean ARU after treatment were also lower in the cilostazol group (456.9 +/- 56.0 vs. 470.7 +/- 67.2, P = 0.081). Cilostazol addition did not prolong bleeding time. Although this was a negative study, our findings disclosed a trend toward enhanced antiplatelet effects when cilostazol was added to aspirin in ischaem...Continue Reading

References

Jan 1, 1990·Seminars in Thrombosis and Hemostasis·R P Rodgers, J Levin
May 20, 1998·American Heart Journal·N S NicholsonA K Salyers
Feb 20, 2002·The British Journal of Surgery·J Smout, G Stansby
Jul 30, 2002·Prostaglandins, Leukotrienes, and Essential Fatty Acids·A CsiszarZ Ungvari
Sep 24, 2002·The Annals of Pharmacotherapy·Patricia A Howard
Dec 11, 2002·Circulation·Jorge RouvierRaúl Altman
Aug 30, 2003·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Didier KehHerwig Gerlach
Oct 16, 2003·Journal of Vascular Surgery·Douglas B WilhiteA Koneti Rao
May 12, 2004·Current Pharmaceutical Design·John F Fullard
Jul 21, 2004·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Joong-Seok KimHideki Takami
Nov 10, 2004·Circulation·Alan D Michelson
Nov 9, 2005·Atherosclerosis. Supplements·William R Hiatt
Mar 15, 2006·The New England Journal of Medicine·Deepak L BhattUNKNOWN CHARISMA Investigators
Aug 23, 2006·The American Journal of Cardiology·Ahmadshah MirkhelMichael Domanski
Jul 3, 2007·The American Journal of Medicine·Wai-Hong ChenChu-Pak Lau
Oct 30, 2007·Clinical Neurology and Neurosurgery·Jung Im SeokOh Young Bang
May 24, 2008·Thrombosis Research·Helle L NielsenAnne-Mette Hvas

❮ Previous
Next ❯

Citations

Apr 22, 2011·Journal of Neurology·Serkan OzbenTomris Ozben
Nov 8, 2011·Journal of Hematology & Oncology·Xuebin Ji, Ming Hou
Apr 5, 2014·Evidence-based Complementary and Alternative Medicine : ECAM·Ai-Ju LiuGuo-Qing Zheng
Jul 31, 2013·Neurologic Clinics·Sarkis G Morales Vidal, Sean Ruland
Mar 5, 2015·International Journal of Stroke : Official Journal of the International Stroke Society·Jong S KimShinichiro Uchiyama
May 10, 2011·Expert Opinion on Pharmacotherapy·Zaid A Al-QudahAdnan I Qureshi
May 3, 2016·Cardiovascular Therapeutics·Ling-Xia XuGuangping Li
Oct 31, 2017·Current Opinion in Neurology·Xinyi LengK S Lawrence Wong
Jun 2, 2017·Korean Circulation Journal·Yongwhi ParkChoong Hwan Kwak
Jul 11, 2020·Stroke; a Journal of Cerebral Circulation·Caroline McHutchisonJoanna M Wardlaw
Feb 11, 2011·Expert Review of Neurotherapeutics·Mehmet Akif TopçuogluHakan Ay
Oct 13, 2012·Experimental and Therapeutic Medicine·Kiyoshi KikuchiEiichiro Tanaka

❮ Previous
Next ❯

Related Concepts

Related Feeds

Brain Ischemia

Brain ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. Discover the latest research on brain ischemia here.